Indian Journal of Clinical Biochemistry

, Volume 34, Issue 1, pp 101–107 | Cite as

Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient’s with Dyslipidemia

  • Noorhan K. ShafeeqEmail author
Original Research Article


In the study, it is aimed to research the likely role of visfatin in hyperthyroid and subclinical hyperthyroid status related to dislipidemia, after determining the visfatin and PON-1 levels thirty healthy individuals were enrolled in this study as control group and thirty hyperthyroidism patient’s with dyslipidemia they were treated with. The subjects aged ranged (30–50) years and with BMI (25–29) kg/m2. Serum was used in determination of lipid profile total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), thyroid threonine (T3) and thyroxin (T4), thyroid stimulating hormone (TSH), visfatin and paraoxonase-1 (PON-1). The results showed significant increase in T3, T4, TC, TG, LDL and VLDL in patient group when comparing to control group. While significant decrease was found in TSH and HDL in patient group when comparing to control group. The results also represented significant increase in visfatin levels in patient group comparing to control group. While there are significant reducation in PON-1 levels in patient group comparing to control group. The conclusion could be drown from this study that visfatin and PON-1 effected hyperthyroidism patient’s with dyslipidemia All the patients in hyperthyroid group were heterozygotes for Familial Hypercholesterolemia is a disorder that is passed down through families. It causes LDL (bad) cholesterol level to be very high. The condition begins at birth and can cause heart attacks at an early age.


Hyperthyroidism patient’s with dyslipidemia Visfatin PON-1 


  1. 1.
    Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, et al. Harper’s illustrated biochemistry. 30th ed. New York: Mc Graw Hill Lange; 2017.Google Scholar
  2. 2.
    Shivanada NB. Manipal manual of clinical biochemistry. 3rd ed. New Delhi: Jaypee brothers medical publishers (P) Ltd; 2008.Google Scholar
  3. 3.
    Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes. 2010;17:408–13.CrossRefGoogle Scholar
  4. 4.
    Reamy BV. Hyperlipidemia management for primary care: an evidence-based approach. 1st ed. New York: Springer; 2009.Google Scholar
  5. 5.
    Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, et al. Nicotinamide phosphoribosyl transferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun. 2010;391(1):376–81.CrossRefGoogle Scholar
  6. 6.
    Costford SR, Bajpeyi S, Pasarica M, Albarado DC, Thomas SC, et al. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab. 2010;98:E117–26.CrossRefGoogle Scholar
  7. 7.
    Gligori R, Zdremtan D, Pilat L, Matei I, Ionescu-Tirgoviste C, Crisnic I. Correlations of visfatin with the lipidic metabolism in diabetic and obese patients. Proc Rom Acad Ser B. 2012;1:37–43.Google Scholar
  8. 8.
    Mancini A, Festa R, Raimondo S, Pontecorvi A, Littarru GP. Hormonal influence on Coenzyme (Q10) levels in blood plasma. Int J Mol Sci. 2011;12:9216–25.CrossRefGoogle Scholar
  9. 9.
    Rajkovic MG, Rumora L, Barisic K. The paraoxonase 1, 2 and 3 in humans. Biochem Med. 2011;21:122–30.CrossRefGoogle Scholar
  10. 10.
    Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol. 2005;11:7351–4.CrossRefGoogle Scholar
  11. 11.
    Bhagwat K. Xanthine oxidase and paraoxonase-1 as new markers in the diagnosis and prognosis of organophosphorus pesticide poisoning. Int J Biol Res. 2013;1(2):10–4.Google Scholar
  12. 12.
    Shekhanawar M, Shekhanawar SM, Krisnaswamy D, Indumati V, Satishkumar D, et al. The role of ‘paraoxonase-1 activity’ as an antioxidant in coronary artery diseases. J Clin Diagn Res. 2013;7(7):1284–7.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Camuzcuoğlu H, Toy H, Vural M, Camuzcuoğlu A, Taşkın A, et al. Serum paraoxonase and arylesterase activities in iron deficiency anemia during pregnancy. Turk J Med Sci. 2011;41:185–91.Google Scholar
  14. 14.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative. Clin Chem. 1972;81:499–502.Google Scholar
  15. 15.
    Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):408–13.CrossRefGoogle Scholar
  16. 16.
    Mondal SI, Das SA, Akter A, Hasan R, Talukdar SA, et al. Thyroid hormone and its correlation with age, sex and serum lipid levels in hypothyroid and euthyroid sylheti populations in Bangladesh. J Clin Diagn Res. 2011;5(7):1347–51.Google Scholar
  17. 17.
    Gholamhoseinian A, Shahouzehi B, Sharifi-far F. Inhibitory activity of some plant methanol extracts on 3-hydroxyl-3-methylglutaryl coenzyme a reductase. Int J Pharmacol. 2010;6(5):705–11.CrossRefGoogle Scholar
  18. 18.
    Oravec S, Gruber K, Dostal E, Mikl J. Hyper-betalipoproteinemia LDL 1,2: a newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuro Endocrinol Lett. 2011;32:322–7.PubMedGoogle Scholar
  19. 19.
    Zheng C, Khoo C, Furtado J, Sacks FM. A polipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Circulation. 2010;121(15):1722–34.CrossRefGoogle Scholar
  20. 20.
    Abbas JMK, Chakraborty J, Akanji AO, Doi SAR. Hypothyroidism results in small dense LDL independent of IRS traits and hypertriglyceridemia. Endocr J. 2008;55:381–9.CrossRefGoogle Scholar
  21. 21.
    Biondi B. How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism? Eur J Endocrinol. 2012;167:295–9.CrossRefGoogle Scholar
  22. 22.
    Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Syndr. 2010;2:21.CrossRefGoogle Scholar
  23. 23.
    Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009;71(2):202–7.CrossRefGoogle Scholar
  24. 24.
    Lu LF, Yang SS, Wang CP, Hung WC, Yu TH, et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis. 2009;18(5):354–9.CrossRefGoogle Scholar
  25. 25.
    Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta. 2009;410(1–2):1–12.CrossRefGoogle Scholar
  26. 26.
    Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke. 2010;41:961–6.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2017

Authors and Affiliations

  1. 1.Chemistry Department, College of Education for Pure Science/Ibn Al-HaithamUniversity of BaghdadAI-Adhamiyah/Anter Square/BaghdadIraq

Personalised recommendations